• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Professor Klaus Dugi - Articles and news items

Boehringer Ingelheim logo

Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy

Industry news / 27 November 2014 / Boehringer Ingelheim

Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for Vargatef® (nintedanib*), valid for the 28 countries within the EU…

Boehringer Ingelheim logo

Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients

Industry news / 9 July 2014 / Boehringer Ingelheim

Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer…

Boehringer Ingelheim logo

Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat® fixed-dose combination in COPD

Industry news / 2 July 2014 / Boehringer Ingelheim

Boehringer Ingelheim announced submission of Marketing Authorisation Applications in 31 European countries for the once-daily fixed-dose combination of tiotropium + olodaterol in the Respimat® Soft Mist™ Inhaler…

Boehringer Ingelheim logo

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote

Industry news / 30 June 2014 / Boehringer Ingelheim

The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to the investigational antidote idarucizumab…

Boehringer Ingelheim logo

Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

Industry news / 17 June 2014 / Boehringer Ingelheim

Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin…

Boehringer Ingelheim logo

Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism

Industry news / 6 June 2014 / Boehringer Ingelheim

Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism…

Boehringer Ingelheim logo

Type 2 Diabetes: European Commission approves Jardiance® (empagliflozin)

Industry news / 23 May 2014 / Boehringer Ingelheim

The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company…

Boehringer Ingelheim logo

New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer

Industry news / 15 May 2014 / Boehringer Ingelheim

Boehringer Ingelheim announced new overall survival results from a post-hoc analysis combining the data of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)…

Boehringer Ingelheim logo

Volasertib, Boehringer Ingelheim´s investigational treatment of acute myeloid leukaemia, is granted ‘orphan drug designation’ in the EU and the US

Industry news / 17 April 2014 / Boehringer Ingelheim

Boehringer Ingelheim announced that the US Food and Drug Administration and the European Commission have granted volasertib* ‘orphan drug designation’ for the treatment of patients with acute myeloid leukaemia…

Boehringer Ingelheim logo

Type 2 Diabetes: CHMP recommends empagliflozin for approval

Industry news / 21 March 2014 / Boehringer Ingelheim

Positive opinion for investigational SGLT2 inhibitor empagliflozin for the treatment of T2D in adults…

Boehringer Ingelheim logo

New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism

Industry news / 10 December 2013 / Boehringer Ingelheim

The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics…

Boehringer Ingelheim logo

New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin in adults newly diagnosed with Type 2 Diabetes

Industry news / 3 December 2013 / Boehringer Ingelheim

The result showed that linagliptin as monotherapy or in initial combination with metformin achieved clinically significant improvements in glucose control in patients with newly diagnosed T2D and marked hyperglycaemia…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +